About CyCa Oncosolutions
CyCa Oncosolutions is a company based in Delaware City (United States) founded in 2017 by Taiyyaba Kausar and Saikh Fazlul Haque Krishnan. CyCa Oncosolutions operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Delaware City, United States
- Founders Taiyyaba Kausar, Saikh Fazlul Haque Krishnan
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cygenica Private Limited
- Date of Incorporation 28 Feb, 2017
- Jurisdiction Baleshwar, Orissa, India
-
Annual Revenue
$184.68 K (USD)5.97as on Mar 31, 2023
-
Net Profit
$22.07 K (USD)-2.55as on Mar 31, 2023
-
EBITDA
$10.21 K (USD)-55.67as on Mar 31, 2023
-
Latest Funding Round
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of CyCa Oncosolutions
Investments & Acquisitions by CyCa Oncosolutions
Financial Statements - CyCa Oncosolutions
Cyca Oncosolutions Comparisons
Competitors of CyCa Oncosolutions
CyCa Oncosolutions operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
Dental implants and regenerative dentistry products are developed.
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
Latest news on Cyca Oncosolutions
Frequently Asked Questions about CyCa Oncosolutions
CyCa Oncosolutions was founded in 2017.
CyCa Oncosolutions is headquartered in Delaware City, United States. It is registered at Delaware City, Delaware, United States.
Annual revenue of CyCa Oncosolutions is $184.68K as on Mar 31, 2023.
CyCa OncoSolutions was founded in 2017 in Delaware City, United States, and operates in the life sciences sector. Drug delivery technology is provided to industry partners through a proprietary non-endocytic cell entry mechanism. Higher cellular uptake is achieved with lower dosages and fewer side effects, according to company claims. Primary application is targeted toward cancer cells.
CyCa Oncosolutions's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.